Alexa Simon Meara
Overview
Explore the profile of Alexa Simon Meara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
67
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elsaid M, Simon Meara A, Owen D
J Clin Oncol
. 2024 Oct;
42(35):4119-4122.
PMID: 39356977
No abstract available.
2.
Rheumatic Immune-Related Adverse Events: Current Clinical Imperatives Underpin Future Novel Insights
Liew D, Simon Meara A
Rheum Dis Clin North Am
. 2024 Apr;
50(2):xvii-xix.
PMID: 38670733
No abstract available.
3.
Ghosh N, Jivanelli B, Couette N, Singh N, Kostine M, Simon Meara A, et al.
Rheum Dis Clin North Am
. 2024 Apr;
50(2):325-335.
PMID: 38670730
Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an immune-related adverse event that can occur as a result of receiving ICIs for cancer treatment. Thus far, ICI-IA has been described variably...
4.
Klionsky Y, Simon Meara A, Reid P
Rheum Dis Clin North Am
. 2024 Apr;
50(2):229-239.
PMID: 38670722
Cancer immunotherapy is revolutionary for survival but has complications due to immunogenicity with unpredictable and potentially long-lasting autoimmune side effects known as immune-related adverse events (irAEs). Currently, treatment beyond corticosteroids...
5.
Hannon C, Goodman S, Austin M, Yates Jr A, Guyatt G, Aggarwal V, et al.
J Arthroplasty
. 2023 Dec;
39(3):851-852.
PMID: 38049357
No abstract available.
6.
Hannon C, Goodman S, Austin M, Yates Jr A, Guyatt G, Aggarwal V, et al.
J Arthroplasty
. 2023 Oct;
38(11):2193-2201.
PMID: 37778918
Objective: To develop evidence-based consensus recommendations for the optimal timing of hip and knee arthroplasty to improve patient-important outcomes including, but not limited to, pain, function, infection, hospitalization, and death...
7.
Hannon C, Goodman S, Austin M, Yates Jr A, Guyatt G, Aggarwal V, et al.
Arthritis Rheumatol
. 2023 Sep;
75(11):1877-1888.
PMID: 37746897
Objective: To develop evidence-based consensus recommendations for the optimal timing of hip and knee arthroplasty to improve patient-important outcomes including, but not limited to, pain, function, infection, hospitalization, and death...
8.
Hannon C, Goodman S, Austin M, Yates Jr A, Guyatt G, Aggarwal V, et al.
Arthritis Care Res (Hoboken)
. 2023 Sep;
75(11):2227-2238.
PMID: 37743767
Objective: To develop evidence-based consensus recommendations for the optimal timing of hip and knee arthroplasty to improve patient-important outcomes including, but not limited to, pain, function, infection, hospitalization, and death...
9.
Ghosh N, Couette N, van Binsbergen W, Weinmann S, Jivanelli B, Shea B, et al.
Semin Arthritis Rheum
. 2022 Nov;
58:152110.
PMID: 36372016
Introduction: Immune checkpoint inhibitors (ICI), increasingly used cancer therapeutics, can cause off-target inflammatory effects called immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis (ICI-induced IA) and polymyalgia rheumatica (ICI-induced PMR)....
10.
Couette N, Jarjour W, Brammer J, Simon Meara A
Front Oncol
. 2022 Jun;
12:854499.
PMID: 35747794
A complex relationship exists between rheumatic diseases and cancer. This delicate balance between chronic inflammation and malignant cell transformation in hematologic neoplasms has been observed, but is not well defined....